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Summary  24 
Intestinal microbiota undergo significant changes in colorectal cancer (CRC). Zheng et al. 25 
(Nature Biomed Eng. 2019) observe detrimental overpopulation of Fusobacterium 26 
nucleatum (F. nucleatum) in mice and patients, suppressing the beneficial butyrate-27 
producing Clostridium butyricum. Phage-guided irinotecan-loaded dextran nanoparticles 28 
promote release of bacterial-derived butyrate, while F. nucleatum and CRC cells are 29 
eliminated. These findings describe a possible novel therapeutic strategy for CRC. 30 
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Colorectal cancer (CRC) is one of the three leading causes of cancer-related deaths 35 
worldwide. This multi-factorial and multi-stage disease impacts the life of millions of 36 
newly-diagnosed patients annually. Due to disease recurrence and metastasis, clinical 37 
management of CRC patients is associated with high healthcare costs. Currently, novel 38 
therapeutic strategies are urgently needed. A recently reported alternative approach has 39 
been to treat patients with bacteriophage (phage) for different pathological conditions. 40 
These bacteria-killing viruses can be classified as lytic or temperate units, as they either 41 
undergo lytic or lysogenic cycles, respectively. Although both events lead to bacterial 42 
destruction, lysogenic events require that viral and bacterial genomes integrate and 43 
replicate during the virus’s dormant phase [1-4]. 44 
 Recently, Zheng et al. [1] identified that CRC patients and ApcMin/+ mice exhibit a 45 
significant increase of Fusobacterium nucleatum (F. nucleatum), which is typically found 46 
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in oral and nasal cavities. As an alien bacterial species to the intestines, F. nucleatum 47 
produces immune blocking agents and competes with the beneficial butyrate-producing 48 
Clostridium butyricum (C. butyricum) units, thus promoting CRC development and 49 
enhancing chemotherapy resistance. In human saliva, the authors isolated a temperate 50 
phage capable of specialized and targeted killing of F. nucleatum without impacting the 51 
C. butyricum population. From this, the authors went on to treat piglets with phage-guided 52 
dextran nanoparticles. Their experiments reveal that in response to this therapeutic 53 
strategy, minimal changes occur in vital metabolic or immunological functions. They 54 
further developed a phage-guided biotic-abiotic hybrid nanosystem that could increase 55 
the chemotherapeutic potency of irinotecan against CRC cells whilst also selectively 56 
killing the F. nucleatum population and allowing the butyrate-producing bacteria to expand 57 
in numbers at the same time. Phages have a long history of usage with varying success 58 
(Figure 1). Careful consideration should thus be given to this exciting discovery, as this 59 
new therapeutic strategy of administering phage-guided irinotecan-loaded dextran 60 
nanoparticles may impact CRC treatment in coming years. 61 
It should be appreciated that the composition of the intestinal phage population 62 
has been reported to be altered at different stages of CRC development. Parabacteroides 63 
phage YZ-2015b units undergo an exponential increase from early to late CRC stages 64 
[5]. In keeping with this idea, adherent invasive Escherichia coli promotes tumor growth 65 
in APCMin/+ mice, while phage treatment has been found capable of increasing survival 66 
and reducing tumor growth in these bacteria-infected mice. However, elimination of 67 
cancer-causing bacteria via phages appears to worsen inflammatory bowel disease, as 68 
they alter the intestinal immunity. Studies have found lower phage levels in responsive 69 
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rather than non-responsive ulcerative colitis patients who received fecal microbiota 70 
transplantation since phages increase the release of interferon  (IFN- ) in this non-71 
responders group [2]. Another study further reveals that colitis changes the intestinal 72 
phage population toward a stochastic state of dysbiosis in mice and humans [3]. 73 
Moreover, intestinal inflammation has been shown to promote bacterial pathogenic 74 
evolution through a disease-driven transfer of temperate phages, as it supports the 75 
expression of phage promoter Tum, free phage production and transfer, and bacterial 76 
SOS response [4]. Collectively, these findings should focus our attention on the fact that 77 
phage therapy may lead to unforeseeable side effects in humans. 78 
 Treating humans with bioengineered phages has, however, been proven a 79 
promising therapeutic strategy in cases where traditional approaches have failed. 80 
Successfully, Spencer and colleagues applied a three-phage cocktail in a teenager 81 
patient who underwent bilateral lung transplantation but had a drug-resistant bacterial 82 
infection. Following 121 days of phage treatment, this patient exhibited a favorable clinical 83 
improvement, including enhanced liver function and significant resolution of infection sites 84 
[6]. Another exciting investigation involved the use of engineered virus-like particles with 85 
multiple IgG-binding ZZ domains from Q  phage capsids. This molecular strategy 86 
enabled the specific elimination of human pluripotent stem cells by 5-fluorocytosine 87 
without impacting on the non-target differentiated cellular population [7]. 88 
 Although the idea of Zhang and colleagues to block CRC development by 89 
enhancing bacteria-producing butyrate through bioengineering-related methods is indeed 90 
remarkable and mechanistically attractive [1], there is a wealth of evidence countenancing  91 
caution to be considered. For instance, dextran has been chemically bound to 2-92 
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nitroimidazole (NI). NI can be metabolized into bioreductive species that block DNA 93 
synthesis and damage several intracellular targets in both eukaryotic and prokaryotic 94 
cells, leading to nonselective cell death. Compounds of this class have indeed been 95 
suggested to act as radiosensitisers [8]. This illustrates the carcinogenic potential that this 96 
class of compounds have been reported to possess [9]. On the other hand, Park et al. 97 
report that Gram-positive commensal bacteria control the intestinal epithelial cell turnover 98 
by releasing short-chain fatty acids [10]. Stappenbeck and colleagues then revealed that 99 
while the short-chain fatty acid butyrate is essential to colonocytes’ metabolism, it inhibits 100 
forkhead box o3 (FOXO3) transcriptional activity impairing proliferation in the colonic stem 101 
cell niche [11]. However, Merchant and colleagues indicated that in Apc mutant stem 102 
cells, in which -catenin signaling is high, butyrate-dependent regulation through zinc 103 
finger DNA-binding protein 89 (ZBP-89) promotes the development of early CRC stages 104 
[12]. These facts should stimulate a thoughtful debate on the diverse effects of butyrate 105 
on stem cells in physiological or malignant colon conditions, as it could significantly impact 106 
cancer relapse and the patient’s overall survival. 107 
We believe that the findings of Zheng et al. embrace a promising and feasible 108 
therapeutic strategy for CRC patients, as it provides a significant advancement in 109 
therapies that strengthens the body’s anticancer mechanisms with chemotherapy. 110 
Further development should shed light on how this type of treatment reinvigorates the 111 
anti-tumor immunity and impacts the behavior of cancer stem cells in CRC cases. 112 
 113 
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Figure legend 143 
Figure 1 – A century of phage research and therapy. Following the discovery of phages 144 
at the beginning of the 20th century, this class of bacteria-killing viruses was successfully 145 
applied in the treatment of a broad range of bacterial infections. However, unfortunate 146 
events impaired the evolution of such therapies in Western countries for more than a half-147 
century. The urgent emerging need for treatments for extensively drug-resistant or totally 148 
drug-resistant bacteria has led the scientific community to revisit the potential application 149 
of phages in treating a wide range of conditions. This has been expanded to include 150 
cancer. 151 
